奥布替尼治疗复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者:多中心、单臂、开放标签、2期研究
这项多中心、单臂、开放标签2期研究纳入80例中国复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者,接受奥布替尼150 mg每日一次单药治疗。独立评审委员会评估的总缓解率为92.5%(74/80),完全缓解率21.3%(17/80);中位随访32.3个月时中位无进展生存期未达到,30个月无进展生存率和总生存率分别为70.9%(95%CI 59.5-79.6)和81.3%(95%CI 70.8-88.2)。
要点
- 独立评审委员会评估总缓解率92.5%(74/80),完全缓解率21.3%(17/80)。
- 中位随访32.3个月时中位无进展生存期未达到,30个月无进展生存率70.9%。
- TP53突变或del(17p)阳性、del(11q)阳性及IGHV未突变患者总缓解率分别为100%、94.7%、93.9%。
核心结论
- 奥布替尼在复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中显示出疗效和安全性,相当数量患者获得完全缓解。
研究设计与样本
- 多中心、单臂、开放标签2期研究,纳入80例符合条件的中国复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者,接受奥布替尼150 mg每日一次单药治疗。
主要发现
- 独立评审委员会评估总缓解率92.5%(74/80),完全缓解21.3%(17/80),部分缓解60.0%(48/80),伴淋巴细胞增多的部分缓解11.3%(9/80)。
- 中位随访32.3个月时中位无进展生存期未达到,30个月无进展生存率70.9%(95%CI 59.5-79.6),总生存率81.3%(95%CI 70.8-88.2)。
- TP53突变阳性或del(17p)阳性患者总缓解率100%,del(11q)阳性患者94.7%,免疫球蛋白重链可变区基因未突变患者93.9%。
- 大多数不良事件为低级别,86.8%的不良事件为1级或2级;近3年随访后近67%的患者仍在接受奥布替尼治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This is single-arm, multi-center, open-label, phase 2 study in 80 eligible Chinese patients, who were treated with monotherapy of orelabrutinib at 150 mg once daily. Overall response rate evaluated by an independent review committee was the primary endpoint, and secondary endpoints include progression-free survival, overall survival, and safety. Independent review committee assessed overall response rate was 92.5% (74/80); complete response 21.3% (17/80), partial response 60.0% (48/80), partial response with lymphocytosis 11.3% (9/80). At a 32.3-month median follow-up, the median progression-free survival had not been achieved, while the 30-month progression-free survival rate and overall survival rates were 70.9% (95% confidence interval [CI], 59.5-79.6) and 81.3% (95% CI, 70.8-88.2), respectively. Orelabrutinib also revealed substantial response in patients with high prognostic risks: overall response rates of patients carrying positive TP53 mutational status or del(17p), del(11q), as well as unmutated immunoglobulin heavy-chain variable region gene were 100%, 94.7%, and 93.9%, respectively. Most adverse events were in low grade, with 86.8% of AEs being Grade 1 or 2. Nearly 67% of patients were still receiving orelabrutinib after almost a 3-year follow-up. In conclusion, Orelabrutinib demonstrated compelling efficacy as well as safety profiles, with a noteworthy number of patients obtaining complete response in refractory or relapsed CLL/SLL.
引用
- Xu W, Zhou K, Wang T, et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am J Hematol. 2023. PMID: 36683422. doi:10.1002/ajh.26826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。